基于APICloud的药物基因组用药指导信息的手机APP的设计与实现（英文）
|
摘要
开发药物基因组相关用药指导查询软件手机APP,可以解决英文数据库阅读不方便,纸质专业书籍信息更新缓慢和查询不便捷等问题。我们归纳提取http://www.pharmgkb.com中"DosingGuidelines"项下的剂量调整信息,http://www.fda.gov/drugs里Science&Research项下"Table of Pharmacogenomic Biomarkers in Drug Labeling"项下相关药物标签中提及的药物基因组信息,并参考权威论著相关基因指导用药信息,利用SQLite构建用药指导信息库,在APICloud软件开发平台上,使用JavaScript编程自建一款基因指导用药的手机APP。本APP收录了目前研究较多、证据级别较高的精准医学药物197种,覆盖了抗凝和抗血小板药物、一般抗肿瘤药和免疫抑制剂、靶向抗肿瘤药、抗精神病药、抗癫痫药、质子泵抑制剂等25类。使用者可以通过输入药品通用名的拼音首字母获取该药特定基因型的临床意义及用药指导信息。基于APICloud开发平台自建的精准医学药物治疗与用药指导查询系统的手机APP可为临床提供实用快捷的药学信息服务。
The mobile APP for medication guidance related to pharmacogenomic is developed to solve various practical problems, such as inconvenient reading of English database, slow updating of paper reference books and lack of shortcut for access.We extracted the medication guidance information related to the pharmacogenomic from ‘Dosing Guidelines’(http://www.pharmgkb.com), ′Table of Pharmacogenomic Biomarkers in Drug Labeling′(http://www.fda.gov/drugs/scienceresearch) and relevant authoritative books.SQLite was used to build the medication guidance information database.We designed and implemented a mobile APP for medication guidance by JavaScript programming language.The APP contained 197 drugs that have been extensively studied and have high levels of evidence.It covered 25 categories, such as anticoagulant and antiplatelet drugs, general antitumor, immunosuppressant drugs, targeted antitumor drugs, antipsychotic drugs, antiepileptic drugs, and proton pump inhibitors and so on.Users can obtain clinical significance and guidance information related to the genotype of the drug by entering the pinyin initials of the generic name of the drug.The mobile APP for medication guidance related to pharmacogenomic based on APICloud could provide practical and convenient pharmaceutical information service for clinical use.
The mobile APP for medication guidance related to pharmacogenomic is developed to solve various practical problems, such as inconvenient reading of English database, slow updating of paper reference books and lack of shortcut for access.We extracted the medication guidance information related to the pharmacogenomic from ‘Dosing Guidelines’(http://www.pharmgkb.com), ′Table of Pharmacogenomic Biomarkers in Drug Labeling′(http://www.fda.gov/drugs/scienceresearch) and relevant authoritative books.SQLite was used to build the medication guidance information database.We designed and implemented a mobile APP for medication guidance by JavaScript programming language.The APP contained 197 drugs that have been extensively studied and have high levels of evidence.It covered 25 categories, such as anticoagulant and antiplatelet drugs, general antitumor, immunosuppressant drugs, targeted antitumor drugs, antipsychotic drugs, antiepileptic drugs, and proton pump inhibitors and so on.Users can obtain clinical significance and guidance information related to the genotype of the drug by entering the pinyin initials of the generic name of the drug.The mobile APP for medication guidance related to pharmacogenomic based on APICloud could provide practical and convenient pharmaceutical information service for clinical use.
引文
[1]Pirmohamed,M.Personalized pharmacogenomics:predicting efficacy and adverse drug reactions.Annu.Rev.Genomics Hum.Genet.2014,15,349-370.
[2]Shuldiner,R.;Relling,V.;Peterson,F.;Hicks,K.;Freimuth,R.;Sadee,W.;Pereira,L.;Roden,M.;Johnson,A.;Klein,E.The pharmacogenomics research network translational pharmacogenetics program:Overcoming challenges of real-world implementation.Clin.Pharmacol.Ther.2013,94,207-210.
[3]Dunnenberger,H.M.;Crews,K.R.;Hoffman,J.M.;Caudle,K.E.;Broeckel,U.;Howard,S.C.;Hunkler,R.J.;Klein,T.E.;Evans,W.E.;Relling,M.V.Preemptive clinical pharmacogenetics implementation:Current programs in five US medical centers.Annu.Rev.Pharmacol.Toxicol.2015,55,89-106.
[4]Anderson,J.L.;Horne,B.D.;Stevens,S.M.;Woller,S.C.;Samuelson,K.M.;Mansfield,J.W.;Robinson,M.;Barton,S.;Brunisholz,K.;Mower,C.P.;Huntinghouse,J.A.;Rollo,J.S.;Siler,D.;Bair,T.L.;Knight,S.;Muhlestein,J.B.;Carlquist,J.F.A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing(Couma Gen-II).Circulation.2012,125,1997-2005.
[5]Kamali,F.;Wynne,H.Pharmacogenetics of warfarin.Annu.Rev.Med.2010,61,63-75.
[6]Nguyen,T.A.;Diodati,J.G.;Pharand,C.Resistance to clopidogrel:A review of the evidence.J.Am.Coll.Cardiol.2005,45,1157-1164.
[7]Guo,Y.M.;Zhao,Z.C.;Zhang,L.;Li,H.Z.;Li,Z.;Sun,H.L.CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.Genet.Mol.Res.2016,15.doi:10.4238/gmr.15028012.
[8]Zhuo,Z.L.;Xian,H.P.;Long,Y.;Liu,C.;Sun,Y.Y.;Ma,Y.T.;Gao,H.;Zhao,J.Z.;Zhao,X.T.Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients.Anatol.J.Cardiol.2018,19,123-129.
[9]Catena,C.;Colussi,G.;Url-Michitsch,M.;Nait,F.;Sechi,L.A.Subclinical carotid artery disease and plasma homocysteine levels in patients with hypertension.J.Am.Soc.Hypertens.2015,9,167-175.
[10]Ford,A.H.;Flicker,L.;Singh,U.;Hirani,V.;Almeida,O.P.Homocysteine,depression and cognitive function in older adults.J.Affect.Disord.2013,151,646-651.
[11]Huo,Y.;Li,J.P.;Qin,X.H.;Huang,Y.N.;Wang,X.B.;Gottesman,R.F.;Tang,G.F.;Wang,B.Y.;Chen,D.F.;He,M.L.;Fu,J.;Cai,Y.F.;Shi,X.L.;Zhang,Y.;Cui,Y.M.;Sun,N.L.;Li,X.Y.;Cheng,X.S.;Wang,J.N.;Yang,X.C.;Yang,T.L.;Xiao,C.S.;Zhao,G.;Dong,Q.;Zhu,D.L.;Wang,X.;Ge,J.B.;Zhao,L.Y.;Hu,D.Y.;Liu,L.S.;Hou,F.F.CSPPT Investigators,Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China:the CSPPT randomized clinical trial.JAMA.2015,313,1325-1335.
[12]Klein,T.E.;Chang,J.T.;Cho,M.K.;Easton,K.L.;Fergerson,R.;Hewett,M.;Lin,Z.;Liu,Y.;Liu,S.;Oliver,D.E.;Rubin,D.L.;Shafa,F.;Stuart,J.M.;Altman,R.B.Integrating genotype and phenotype information:An overview of the PharmGKB project.Pharmacogenetics Research Network and Knowledge Base.Pharmacogenomics J.2001,1,167-170.
[13]Thorn,C.F.;Klein,T.E.;Altman,R.B.Pharmacogenomics and bioinformatics:PharmGKB.Pharmacogenomics.2010,11,501-505.
[14]Zhang,G.Q.;Zhang,Y.S.;Ling,Y.C.;Jia,J.Web resources for pharmacogenomics.Genomics Proteomics Bioinformatics.2015,13,51-54.
[2]Shuldiner,R.;Relling,V.;Peterson,F.;Hicks,K.;Freimuth,R.;Sadee,W.;Pereira,L.;Roden,M.;Johnson,A.;Klein,E.The pharmacogenomics research network translational pharmacogenetics program:Overcoming challenges of real-world implementation.Clin.Pharmacol.Ther.2013,94,207-210.
[3]Dunnenberger,H.M.;Crews,K.R.;Hoffman,J.M.;Caudle,K.E.;Broeckel,U.;Howard,S.C.;Hunkler,R.J.;Klein,T.E.;Evans,W.E.;Relling,M.V.Preemptive clinical pharmacogenetics implementation:Current programs in five US medical centers.Annu.Rev.Pharmacol.Toxicol.2015,55,89-106.
[4]Anderson,J.L.;Horne,B.D.;Stevens,S.M.;Woller,S.C.;Samuelson,K.M.;Mansfield,J.W.;Robinson,M.;Barton,S.;Brunisholz,K.;Mower,C.P.;Huntinghouse,J.A.;Rollo,J.S.;Siler,D.;Bair,T.L.;Knight,S.;Muhlestein,J.B.;Carlquist,J.F.A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing(Couma Gen-II).Circulation.2012,125,1997-2005.
[5]Kamali,F.;Wynne,H.Pharmacogenetics of warfarin.Annu.Rev.Med.2010,61,63-75.
[6]Nguyen,T.A.;Diodati,J.G.;Pharand,C.Resistance to clopidogrel:A review of the evidence.J.Am.Coll.Cardiol.2005,45,1157-1164.
[7]Guo,Y.M.;Zhao,Z.C.;Zhang,L.;Li,H.Z.;Li,Z.;Sun,H.L.CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.Genet.Mol.Res.2016,15.doi:10.4238/gmr.15028012.
[8]Zhuo,Z.L.;Xian,H.P.;Long,Y.;Liu,C.;Sun,Y.Y.;Ma,Y.T.;Gao,H.;Zhao,J.Z.;Zhao,X.T.Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients.Anatol.J.Cardiol.2018,19,123-129.
[9]Catena,C.;Colussi,G.;Url-Michitsch,M.;Nait,F.;Sechi,L.A.Subclinical carotid artery disease and plasma homocysteine levels in patients with hypertension.J.Am.Soc.Hypertens.2015,9,167-175.
[10]Ford,A.H.;Flicker,L.;Singh,U.;Hirani,V.;Almeida,O.P.Homocysteine,depression and cognitive function in older adults.J.Affect.Disord.2013,151,646-651.
[11]Huo,Y.;Li,J.P.;Qin,X.H.;Huang,Y.N.;Wang,X.B.;Gottesman,R.F.;Tang,G.F.;Wang,B.Y.;Chen,D.F.;He,M.L.;Fu,J.;Cai,Y.F.;Shi,X.L.;Zhang,Y.;Cui,Y.M.;Sun,N.L.;Li,X.Y.;Cheng,X.S.;Wang,J.N.;Yang,X.C.;Yang,T.L.;Xiao,C.S.;Zhao,G.;Dong,Q.;Zhu,D.L.;Wang,X.;Ge,J.B.;Zhao,L.Y.;Hu,D.Y.;Liu,L.S.;Hou,F.F.CSPPT Investigators,Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China:the CSPPT randomized clinical trial.JAMA.2015,313,1325-1335.
[12]Klein,T.E.;Chang,J.T.;Cho,M.K.;Easton,K.L.;Fergerson,R.;Hewett,M.;Lin,Z.;Liu,Y.;Liu,S.;Oliver,D.E.;Rubin,D.L.;Shafa,F.;Stuart,J.M.;Altman,R.B.Integrating genotype and phenotype information:An overview of the PharmGKB project.Pharmacogenetics Research Network and Knowledge Base.Pharmacogenomics J.2001,1,167-170.
[13]Thorn,C.F.;Klein,T.E.;Altman,R.B.Pharmacogenomics and bioinformatics:PharmGKB.Pharmacogenomics.2010,11,501-505.
[14]Zhang,G.Q.;Zhang,Y.S.;Ling,Y.C.;Jia,J.Web resources for pharmacogenomics.Genomics Proteomics Bioinformatics.2015,13,51-54.